Key result
Higher platelet glycoprotein IIb/IIIa receptor occupancy after eptifibatide therapy was associated with improved epicardial patency and ST-segment resolution.
Why the study?
Does higher platelet receptor occupancy after eptifibatide therapy improve epicardial patency, myocardial perfusion, and ST-segment resolution in STEMI patients?
Observational (n=70)
Does higher platelet receptor occupancy after eptifibatide therapy improve epicardial patency, myocardial perfusion, and ST-segment resolution in STEMI patients?
Higher platelet glycoprotein IIb/IIIa receptor occupancy after eptifibatide and tenecteplase therapy is associated with better angiographic and electrocardiographic reperfusion outcomes in STEMI.
Answers are grounded in this paper and cite their sources.
Association may inform occupancy-guided dosing in STEMI; hypothesis-generating and should not yet change practice.
BACKGROUND: Paradoxically, fibrinolytic agents may systemically activate platelets, which in turn secrete plasminogen activator inhibitor (PAI-1), an antagonist of the fibrinolytic process in proportion to total body platelet mass. We hypothesized that improved epicardial patency, myocardial perfusion, and ST-segment resolution would be associated with higher levels of platelet receptor occupancy (RO) by a glycoprotein IIb/IIIa antagonist in ST-elevation MI (STEMI). METHODS AND RESULTS: Patients were drawn from the low-dose tenecteplase plus eptifibatide arm of the INTEGRITI study. Angiographic and platelet RO data were analyzed at 2 independent core laboratories. To take into account the absolute platelet count and receptors available for cross-linking, absolute platelet count was multiplied by percent of available receptors to obtain the index of the absolute number of receptors available (IANRA). Percent RO was higher among patients with a patent artery (TIMI flow grade 2/3; 78.2+/-9.2, n=63 versus 63.9+/-29.7, n=7; P=0.005), those with TIMI myocardial perfusion grade 2/3 (79.6+/-9.5, n=40 versus 73.0+/-16.2, n=30; P=0.036), and those with complete (> or =70%) ST-segment resolution at 60 minutes (81.3+/-8.3%, n=27 versus 73.1+/-17.4%, n=24; P=0.034). The absolute number of glycoprotein IIb/IIIa receptors available for cross-linking was reduced (ie, the IANRA was lower) among patients with a patent artery (P=0.0015), patients with TIMI myocardial perfusion grade 2/3 (P=0.026), and patients with > or =70% ST-segment resolution (P=0.029). CONCLUSIONS: This study links restoration of epicardial flow, normal myocardial perfusion, and complete ST-segment resolution with higher levels of platelet glycoprotein IIb/IIIa receptor occupancy after therapy with eptifibatide administered with tenecteplase.
No takes yet. Share an insight, caveat, or question.
Gibson et al. (2004) conducted an observational in ST-segment-elevation myocardial infarction (STEMI) (n=70). Higher platelet receptor occupancy (RO) vs. Lower platelet receptor occupancy was evaluated on Patent artery (TIMI flow grade 2/3) (p=0.005). Higher platelet glycoprotein IIb/IIIa receptor occupancy after eptifibatide therapy was associated with improved epicardial patency and ST-segment resolution.
Synapse has enriched 10 related papers. Consider them for comparative context: